Hepatitis C viral (HCV) infection is the leading cause of liver failure and still represents a
global health burden. Over the past decade, great advancements made HCV curable, and …

HCV NS5A inhibitors are the backbone of directly acting antiviral treatments against the
hepatitis C virus (HCV). While these therapies are generally highly curative, they are less …

Herein, novel hepatitis C virus NS3/4A protease inhibitors based on a P2
pyrimidinyloxyphenylglycine in combination with various regioisomers of an aryl acyl …

Hepatitis C virus (HCV) currently infects over 185 million individuals around the world. Its
persistence causes infected individuals to enter a chronic phase where their condition can …

In a follow-up to our recent disclosure of P2− P4 macrocyclic inhibitors of the hepatitis C
virus (HCV) NS3 protease (eg, 1, Chart 1), we report a new but related compound series …

Herein, we present the design and synthesis of 2 (1H)-pyrazinone based HCV NS3 protease
inhibitors and show that elongated R 3 urea substituents were associated with increased …

The nonstructural (NS) protein NS3/4A protease is a critical factor for hepatitis C virus (HCV)
maturation that requires activation by NS4A. Synthetic peptide mutants of NS4A were found …

From l-α-aminobutyric acid (Abu) a set of electrophilic and non-electrophilic replacements
for the P1 cysteine of substrate and product inhibitors of hepatitis C virus full-length NS3 …

Starting from the previously reported HCV NS3/4A protease inhibitor BILN 2061 (1), we have
used a fast-follower approach to identify a novel series of HCV NS3/4A protease inhibitors in …

The virally encoded serine protease NS3/NS4A is essential to the life cycle of the hepatitis C
virus (HCV), an important human pathogen causing chronic hepatitis, cirrhosis of the liver …